menu
    • menu
    [{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Taro Pharmaceutical Industries","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Taro Pharmaceutical Industries"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATB-352","moa":"Mu opioid receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Antibe Therapeutics

    Menu

    Antibe Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Taro Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sun Pharma Subsidiary Taro Acquires Antibe Therapeutics

                            Details : Through the acquisition, Taro will leverage Antibe pipeline, including ATB-346 (otenaproxesul), a novel NSAID. It is being evaluated for the treatment of Osteoarthritis.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 16, 2025

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Taro Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

                            Details : ATB-346 (otenaproxesul) is a novel hydrogen sulfide-releasing, nonsteroidal anti-inflammatory drug, which is being evaluated for the treatment of acute pain.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 04, 2024

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Initiates First Clinical Study of Otenaproxesul’s New Formulation

                            Details : ATB-346 (otenaproxesul) is a novel NSAID that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

                            Details : ATB-346 (otenaproxesul) is a novel NSAID that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 28, 2023

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Reports PK Results of First Clinical Study of Otenaproxesul’s New Formulation

                            Details : ATB-346 (otenaproxesul) is a novel NSAID that releases hydrogen sulfide. Antibe is leveraging the drug's remarkable potency, gastrointestinal ("GI") protection and overall safety profile for use in acute pain indications.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 11, 2023

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Completes First Clinical Study of Otenaproxesul’s New Formulation

                            Details : ATB-346 (otenaproxesul) ia a COX-2 inhibitor which is in clinical development as a safer alternative to opioids and today’s NSAIDs that releases hydrogen sulfide, for acute pain.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 11, 2023

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Provides Development Update for Otenaproxesul

                            Details : The new formulation’s benefits include rapid dissolution mechanics, accelerating otenaproxesul’s (ATB-346) onset of action, a key benchmark for acute pain medications; and enhanced bioavailability, enabling a significant dose reduction compared to it...

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 10, 2022

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

                            Details : ATB-346 (otenaproxesul) is novel nonsteroidal anti-inflammatory drug (“NSAID”) that releases hydrogen sulfide. Antibe is leveraging the drug’s remarkable potency, gastrointestinal (“GI”) protection and overall safety profile for use in acute pa...

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 09, 2022

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Nuance Pharma

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Antibe Therapeutics Announces Strategic Licensing Deal in China with Nuance Pharma

                            Details : The license provides Nuance with exclusive rights to commercialize otenaproxesul in China, Hong Kong, Macau, and Taiwan, representing approximately 10% of the worldwide pharma market.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : $20.0 million

                            September 02, 2021

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Nuance Pharma

                            Deal Size : $100.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Antibe Therapeutics

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Veristat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Antibe Therapeutics Receives FDA Clearance of IND Application for Otenaproxesul for Osteoarthritis Pain

                            Details : Antibe’s lead drug, otenaproxesul, is entering Phase III for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-protective alternative to low-dose aspirin.

                            Product Name : ATB-346

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 29, 2021

                            Lead Product(s) : Otenaproxesul

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Veristat

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth